Articles tagged with: BT-062

News»

[ by and | Dec 11, 2013 6:20 pm | Comments Off ]
ASH 2013 Multiple Myeloma Update - Day Three: Afternoon Oral Sessions

Monday was the third day of this year’s meeting of the American Society of Hematology (ASH).  The day was filled with oral presentation sessions from early in the morning until into the evening.

In the afternoon and early evening, there were six oral presentation sessions devoted solely to multiple myeloma and a number of other myeloma-related presentations scattered about the afternoon.  The topics of these presentations ranged from the biology of myeloma to treat­ment options for newly diag­nosed, re­lapsed and refractory, and older patients.

This ASH update highlights most of the oral …

Read the full story »

News»

[ by | Nov 18, 2013 10:22 pm | Comments Off ]
ASH 2013 Preview: Treatments In Early-Phase Clinical Development For Multiple Myeloma

This article is the second in The Beacon’s ‘preview’ series about mye­lo­ma re­search that will be pre­sented at the American Society of Hema­tol­o­gy (ASH) meet­ing in early December.

Abstracts for the ASH presentations are now available; these abstracts contain pre­lim­i­nary data, and updated data will be presented at the meet­ing.

The Beacon's ASH preview articles, which will be published over the next couple of weeks, will highlight the most interesting myeloma-related studies that will be presented at the meeting.

The first preview, which was published last …

Read the full story »

News»

[ by and | May 24, 2013 4:23 pm | 8 Comments ]
The Future Of Treatment For Multiple Myeloma

In a recent review article pub­lished in the journal Clinical Cancer Re­search, two myeloma experts from the Dana-Farber Cancer In­sti­tute, Dr. Nikhil Munshi and Dr. Kenneth Anderson, review the latest strategies in the treat­ment of mul­ti­ple myeloma.

In their article, the experts discuss newer ther­a­pies that appear to be promising in clin­i­cal and pre­clin­i­cal stud­ies.

According to the physicians, com­bi­na­tion ther­a­pies that spe­cif­i­cally target a patient’s ge­netic form of the dis­ease will be re­quired for long-term dis­ease con­trol and ultimately a cure.

Some Historical Perspective

In their review article, Drs. Munshi and …

Read the full story »

News»

[ by | Dec 12, 2012 2:57 pm | Comments Off ]
ASH 2012 Multiple Myeloma Update – Day Three: Poster Sessions

Monday was the third and next-to-last day of the 2012 American Society of Hematology (ASH) annual meeting.

It also was the busiest day of the meeting in regard to myeloma-related research.

The day ended with a poster session in the evening that featured over 1000 posters displayed throughout a large conference hall.  More than a hundred of the posters reported on the results of myeloma-related research.

Compared to the research summarized during oral presentations, the findings in poster summaries generally are in earlier stages of development.  They may involve laboratory research, clinical …

Read the full story »

NewsFlash »

[ by | Jul 26, 2012 12:35 pm | Comments Off ]

Biotest AG Starts Clinical Trial Of BT-062 Combination Therapy – The German pharma­ceu­tical com­pany Biotest AG has begun a Phase 1/2 clinical trial of BT-062 in com­bi­na­tion with Revlimid (lena­lido­mide) and dexamethasone (Decadron) in patients with re­lapsed and/or refractory multiple myeloma. BT-062 consists of a chemotherapeutic drug com­bined with an anti­body that helps deliver the drug to myeloma and other cancer cells. BT-062 alone has dem­onstrated anti-myeloma activity and good tolerability in re­lapsed and refractory myeloma patients. Furthermore, preclinical studies have shown BT-062 to be more effective when com­bined with Revlimid. For more in­­for­ma­tion, please see the Biotest AG press release and the clinical trial description.

Kyprolis And Oprozomib May Decrease Bone Damage In Multiple Myeloma – The results of a preclinical study suggest that Kyprolis (carfilzomib) and oprozomib may prevent bone loss in multiple myeloma. Kyprolis and oprozomib are both being developed by Onyx Pharmaceuticals, and both belong to the same class of drugs as Velcade (bor­tez­o­mib), known as proteasome inhibitors. Kyprolis was approved last week by the U.S. Food and Drug Administration for the treat­ment of people with multiple myeloma who have received at least two prior ther­a­pies (see related Beacon news). Oprozomib, which will be admin­istered orally, is still in the early clinical devel­op­ment phase. In this study, researchers found that car­filz­o­mib and oprozomib enhanced bone formation and decreased bone destruction in healthy mice. Additionally, in mice with multiple myeloma, treat­ment with car­filz­o­mib or oprozomib resulted in a smaller tumor burden and prevented bone destruction. For more in­­for­ma­tion, please see the study in Leukemia (abstract).

NDC May Overcome Multidrug Resistance And Prevent Doxorubicin-Induced Heart Disease In Myeloma Patients – The results of a recent preclinical study show that a doxorubicin-curcumin com­­pound called NanoDoxCurc (NDC) may overcome resistance to doxorubicin (Adriamycin) while preventing treat­ment-related heart disease. Doxorubicin is a common anticancer agent that becomes less effective in cancer cells demonstrating multidrug resistance. In higher doses, doxorubicin can overcome multidrug resistance, but is also asso­ci­ated with heart disease. In this study, NDC-treated mice with multiple myeloma dem­onstrated lower tumor burdens than mice treated with doxorubicin alone. Furthermore, mice treated with NDC did not experience heart com­pli­ca­tions. The study investigators believe these findings indicate that NDC may be a safe and long-lasting cancer ther­apy. For more in­­for­ma­tion, please see the study in Oncotarget.

BCMA Levels May Be A Disease Marker In Multiple Myeloma – In a recent study, researchers found that B-cell maturation antigen (BCMA) levels in the blood are elevated in multiple myeloma patients and are asso­ci­ated with disease status and over­all survival. BCMAs can be found on the surface of both normal and cancerous B-cells, a type of white blood cell. In the current study, BCMA levels in the blood were higher in multiple myeloma patients compared to those in healthy adults. Furthermore, patients with progressive disease dem­onstrated higher BCMA levels than those who were responsive to treat­ment. After a median follow-up time of 11 months, patients with BCMA levels above the median had shorter over­all survival times than patients below the median. For more in­­for­ma­tion, please see the study in the British Journal of Haematology (abstract).

News»

[ by and | Jan 18, 2012 3:21 pm | 3 Comments ]
BT-062 Shows Activity In Patients With Advanced Myeloma (ASH 2011)

The results of a small Phase 1 clinical trial demonstrate that BT-062, a new drug specifically targeting multiple myeloma cells, shows activity and is tolerable in heavily pretreated multiple myeloma patients.

Dr. Sundar Jagannath of the Mount Sinai Medical Center in New York City presented the results at the 2011 American Society of Hematology (ASH) conference in San Diego last month.

Based on the favorable safety and activity of BT-062, a Phase 1/2 clinical trial has been initiated and is currently recruiting patients. It will use a more frequent dosing …

Read the full story »

News»

[ by | Dec 13, 2011 5:21 pm | One Comment ]
ASH 2011 Multiple Myeloma Update – Day Three Morning: New Therapies

Yesterday was the third day of the American Society of He­ma­tol­ogy (ASH) 2011 Annual Meeting in San Diego, and it was packed full with mul­ti­ple myeloma-related pre­sen­ta­tions. Presentations started early in the morn­ing and con­tinued through the afternoon.

The morn­ing pre­sen­ta­tions about po­ten­tial new myeloma ther­a­pies will be covered in this up­date, and pre­sen­ta­tions from the rest of the day will be covered in addi­tional up­dates.

MLN9708

During the first talk of the day, Dr. Paul Richardson from the Dana-Farber Cancer In­sti­tute in Boston pre­sented re­­sults from a Phase 1 study of …

Read the full story »